Fort Lee, New Jersey, USA, March 24, 2015 (GLOBE NEWSWIRE) -- Herborium® Group, Inc. (OTC Pink: HBRM), www.Herborium.com, a Botanical Therapeutics® Company and the provider of unique all botanical medicines (Botanical Therapeutics®) announced today that last week its Board of Directors approved an increase in the number of Company authorized common shares to 10 billion shares.
Herborium revenues during past two years more than tripled and the Company is moving forward with expanding its presence in a number of markets including:
· UK where it is working with HUT Group, LLC. , the UK's leading multi-website online retailer of Health and Beauty products with a goal of £500,000.00 ($785,000.00) in sales within next 18-24 months;
· France, where the company has increased its sales over 5 fold since 2013;
· Asia, where Herborium is presently forming valuable market partnerships.
In addition, the company has dramatically increased its sales through third party platforms like Amazon and affiliate programs and is expending this strategy to Europe and Japan.
This rapid growth has opened opportunities for Herborium to look not only for new markets and distribution channels but also to develop and acquire new products and enter into new and more mature business partnerships and alliances. The increase in authorized common shares supplements our financing objectives to underwrite these new initiatives.
In addition, this business progress has positioned the Company to further implement its plan to uplist the trading platform for its common shares and to return to full SEC reporting status in 2015. Our goal is to increase shareholder value through our strategic plan to enhance shareholder liquidity.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company that develops, license and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium has secured a pipeline of botanical ingredients based products in the areas of dermatological needs, wellness and energy, prostate health, women's health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, diabetes, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. For more information, please visit www.herborium.com, www.acnease.com. www.acnease.fr.
Safe Harbor Statement: This release contains forward-looking statements with respect to the results of operations and business of Herborium Group, Group, Inc., which involves risks and uncertainties. The Company's actual future results could materially differ from those discussed. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward looking statements be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.